Video Lectures
State-of-the-industry video lectures by leading urology experts
Latest Videos

SAN FRANCISCO, CA USA (UroToday.com) - Presented by Sophie D. Fosså, MD, PhD at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

The Norwegian Radium Hospital, Oslo, Norway 

Click HERE to read an exclusive report by a UroToday medical writer

______________________________

 

Abstract:

Background: After a median observation time of 7.6 years, Scandinavian Prostate Cancer Group VII randomized trial showed a significant 12% reduction of prostate cancer-specific mortality in patients with locally advanced or histologically aggressive prostate cancer who received three months of total androgen blockade followed by radiotherapy and continuous antiandrogen therapy compared to patients with hormonal treatment only (Widmark et al: Lancet [2009]; 373,1174). Here we provide the 10 (15)-year survival results after a median observation time of 10.7 years.

gucancerssympalt thumbMethods: Between February 1996 and December 2002, 875 patients with locally advanced prostate cancer were randomized (Randomization ratio 1:1). Primary endpoint was prostate cancer-specific survival analyzed by intention to treat. This updated analysis is based on death registry data of the Norwegian patients (2/3 of the population), and on data recorded in CRF database available for the Swedish patients. A Swedish death registry analysis is underway, and will be included in the final analysis at the meeting.

Results: Prostate cancer death occurred in 118 out of 439 of the antiandrogen treatment group and in 45 out of 436 men in the combination treatment group (p< 0.0001), with death due to any cause in 210 out of 439 and 161 out of 436 men (p=0.0006), respectively. The 10 (15) year cumulative prostate cancer-specific mortality was more than halved after combined treatment: 18.9% (30.7%) and 8.3% (12.4%) (HR=0.35;[p < 4.1E-10 for 15 year results]), and overall mortality was 35.3% (56.7%) and 26.4% (43.4%) (HR=0.70; P=0.0006 for 15 year results), respectively.

Conclusions: Addition of local radiotherapy to hormonal treatment in patients with non-metastatic locally advanced or high-risk prostate cancer more than halved the 10 and 15 year prostate cancer-specific mortality and substantially decreased overall mortality.

Author(s): Sophie D. Fossa, Anders Widmark, Olbjorn Harald Klepp, Fredrik Wiklund, Anders Angelsen, Jan-Erik Damber; Oslo University Hospital, Oslo, Norway; Umea University, Umea, Sweden; Department of Oncology, Ålesund Hospital, Ålesund, Norway; Karolinska Sjukhus, Stockholm, Sweden; St. Olav's University Hospital, Trondheim, Norway; Urologmottagningen, Goteborg, Sweden

 

 

Calendar
Upcoming urology industry events
June 23-26, 2018 /
2018 CUA Annual Meeting
July 9-12, 2018 / Tan Tock Seng Hospital
Urology Residents' Course Singapore 2018
July 13-14, 2018 / Manchester Grand Hyatt San Diego
Best of ASCO 2018 - San Diego
Journals
Print publications focusing on urological cancer treatments through original commentary & articles
Everyday Urology Volume 2 Issue 4

Everyday Urology™ - Oncology Insights

From the Editor

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor